Omega-3 treatment for high-risk heart plaques
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a purified omega-3 fatty acid called icosapent ethyl can reduce inflammation and shrink high-risk plaques in your heart arteries. It uses a special PET/CT scan to see if the medicine helps stabilize these plaques over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are on a steady dose of cholesterol-lowering medication (like a statin) for at least 4 weeks.
- You have a fasting blood triglyceride level below 5.6 mmol/L.
- A CT scan of your heart shows at least one high-risk plaque feature (for example, a 'napkin-ring sign' or 'spotty calcification').
- You have not had a heart attack, stroke, or heart procedure in the last 3 months.
- You are not taking certain immune-suppressing or high-dose anti-inflammatory medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a prescription fish-oil medicine called icosapent ethyl can improve heart health by reducing plaques (fatty deposits) in the arteries, lowering inflammation, and helping the heart remodel (recover) after a heart event. It is designed for people with heart disease and high triglycerides.
This study tests whether a medication called a PCSK9 inhibitor (a type of drug that lowers bad cholesterol) can improve the buildup of plaque in heart arteries. It may be an option for people with coronary artery disease who have not been helped enough by statins alone.
This trial tests whether adding a special scan to look at the fatty plaque in your arteries can help your doctor decide if you need stronger heart medication to prevent future heart attacks or strokes. If you have moderate blockages and signs of inflammation, you may be able to join.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
This trial compares treatments for heart patients who have a dangerous, but not fully blocking, fatty plaque in their arteries. It aims to see if treating these plaques with a stent or balloon can prevent future heart problems.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.